Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bicara Therapeutics Inc.

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicara Therapeutics Inc.
Via GlobeNewswire
Tickers BCAX
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
From Bicara Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.